Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AACE, Abbvie, abnormal, academic, Actient, adult, adulthood, aggravated, AHU, almotriptan, Alsuma, Amerge, Analog, Androderm, Androgel, ankylosing, anniversary, autoinjector, automatic, automatically, Aveed, Axert, Axiron, biopsy, blockbuster, bone, breach, Bristol, buccal, build, building, certainty, characteristic, characterized, Climara, clot, cognition, complementary, CompleoTRT, contact, correctly, costlier, coupled, cream, Crohn, crossover, database, Dave, deciliter, Delatestryl, density, diagnosed, diminishing, disability, disabling, disproportionately, dissatisfaction, Ditropan, donut, DosePro, draft, eletriptan, embolism, energy, erectile, esterified, Estrace, excessive, faster, fat, Fifty, footage, formula, formulary, Fortesta, Foundation, Frova, frovatriptan, gap, GlaxoSmithKline, hand, HAQ, head, headache, heart, heavily, heavy, hole, idiopathic, Imitrex, Impax, implantable, Importantly, inclined, inflamed, infrastructure, intolerant, Janssen, JIA, juvenile, Kabi, Kaushik, language, lean, learn, lethargy, libido, licensee, lowest, LTIP, Lynch, Maxalt, Meda, Medco, Medicaid, Medicare, medicine, Merrill, MINE, mineral, mm, mood, moved, Myrbetriq, naratriptan, NASDAQ, nausea, Nebido, Nestragel™and, NOL, nondeductible, oil, otrexup, Par, payer, PDUFA, peak, persist, persuasive, pharmacoeconomic, pharmacovigilance, pharmacy, PK, plaque, polycythemia, PPACA, Premarin, proliferation, proposition, psoriatic, pulsating, quantity, Questionnaire, QuickShot, RA, rebate, recalcitrant, recruit, red, relationship, relieve, Relpax, renew, renewed, repeatedly, restore, restored, rheumatic, rheumatological, rheumatology, rizatriptan, roughly, round, routine, safer, sampling, SC, scaly, score, screened, screening, serum, session, shortly, simulated, slowly, sort, split, statdose, stigma, strength, Striant, sumatriptan, Sumavel, summative, Sun, symptomatic, synergistic, teaching, team, technique, Testim, Testopel, thick, thirty, tier, tiered, timeframe, train, training, Trimel, triptan, TRT, UK, ulcerative, undecanoate, UNRESOLVED, Vagifem, vaginal, VAS, Visual, weekly, widening, write, XL, zolmitriptan, Zomig
Removed:
actuation, ago, anesthesia, angina, anturol, appealing, array, ASC, aspect, ASU, ATD, barrier, biopharmaceutical, bolster, Boulevard, cartridge, cessation, circulation, circulatory, clonidine, collectibility, Combining, commencing, compatible, compromise, concentration, contraception, contrast, cosmetically, create, creation, Datamonitor, deemed, defining, delaying, depot, diclofenac, digestive, discomfort, discontinuing, disintegrating, economically, element, employed, engineered, enhanced, essentially, EZ, facilitating, female, fentanyl, FSD, hamper, hidden, hypertension, hypogonadism, incurring, inflammation, ingested, instance, integral, interrupt, investigational, irritant, irritation, kind, LibiGel, lidocaine, limitation, living, locally, metabolite, minimized, monthly, movement, niche, nicotine, nitroglycerin, noncompetitive, norelgestimate, occlusive, opposed, organ, originating, OTC, payor, penetrate, penetrating, physicochemical, planning, plasma, plastic, popular, precise, precision, prepaid, pressurized, prevail, priced, promote, prospective, psychological, ratably, realizing, refund, reliable, render, repayment, reservoir, residence, residual, retrospective, reversal, scopolamine, semisolid, separable, smoking, soft, solubilization, stopper, subdermal, succeed, surface, systemically, tablet, technological, topically, toxicology, transdermally, transported, typical, uncertainty, underlying, urge, viable, viewed, wider
Filing tables
Filing exhibits
- 10-K Annual report
- 10.13 Amendment 2012-1 to Senior Management Agreement
- 10.16 Amendment 2012-1 to Amended and Restated Employment Agreement
- 10.18 Amendment 2012-1 to Employment Agreement
- 10.22 First Amendment to Lease
- 21.1 Subsidiaries of the Registrant
- 23.1 Consent of KPMG LLP, Independent Registered Public Accounting Firm
- 31.1 Certification of the CEO Required by Rule 13A-14(A)
- 31.2 Certification of the CFO Required by Rule 13A-14(A)
- 32.1 Certification of the CEO Required by Rule 13A-14(B)
- 32.2 Certification of the CFO Required by Rule 13A-14(B)
- 99.1 Press Release, Dated March 13, 2013
ATRS similar filings
Filing view
External links
Exhibit 32.1
ANTARES PHARMA, INC.
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. 1350)
The undersigned, Dr. Paul K. Wotton, the Chief Executive Officer of Antares Pharma, Inc. (the “Company”), has executed this Certification in connection with the filing with the Securities and Exchange Commission of the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 (the “Report”).
The undersigned hereby certifies that:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
IN WITNESS WHEREOF, the undersigned has executed this Certification as of the 13th day of March, 2013.
/s/ Paul K. Wotton |
Dr. Paul K. Wotton President and Chief Executive Officer |